How Tesamorelin Listings Indicate Fill Volume vs. Peptide Content
A plain-language breakdown of how tesamorelin listings separate fill volume from labeled peptide mass, and why the two figures are not interchangeable.
Reviewed by Yuki Tanaka, PhD, molecular biologist ·
Yuki Tanaka, PhD is a molecular biologist with a doctorate from Osaka University and postdoctoral training at Stanford School of Medicine, specializing in growth hormone axis biology, GHRH receptor signaling, and synthetic peptide analog mechanisms.
Tesamorelin listings routinely show two different kinds of numbers on the same label, and the two are easy to conflate. One number describes how much liquid a vial holds once reconstituted with bacteriostatic or sterile water. The other describes how much peptide mass, in milligrams, was weighed into the vial before it was lyophilized. Understanding how tesamorelin listings indicate fill volume versus labeled peptide content is the difference between reading a spec sheet correctly and misreading a concentration entirely.
Two Separate Measurements, One Label
A lyophilized tesamorelin vial contains a dried peptide cake, not a liquid. Nothing is “filled” to a particular volume until a buyer or lab adds a diluent. So when a listing shows something like “2 mg vial,” that figure refers strictly to the mass of peptide sealed into the vial during manufacturing. It says nothing about how much liquid will eventually sit above the peptide once reconstituted, because that volume is chosen afterward, not fixed at the factory.
Fill volume, by contrast, only becomes meaningful at the reconstitution step. It refers to the amount of bacteriostatic water or sterile water added to the dried peptide to bring it back into solution. A listing that states a fill volume alongside its peptide mass — for example, “reconstitute with 2 mL” — is giving a suggested dilution figure, not a second measurement of peptide quantity. The peptide mass stays fixed; the fill volume is a variable chosen by whoever performs the reconstitution.
Why Listings Separate the Two Figures
Reputable listings keep these figures visually and numerically distinct because collapsing them into a single number invites a specific error: assuming that a larger vial, or a vial marked with a larger liquid volume, automatically contains more peptide. It does not. A supplier could ship a 2 mg vial with instructions to reconstitute in 1 mL or in 5 mL — the peptide content is identical in both cases, only the resulting concentration differs.
Clear listings typically present this as two labeled lines rather than one combined figure: a peptide content line stating milligrams of tesamorelin, and a separate reconstitution guidance line stating a suggested diluent volume. Some listings omit the second line entirely and leave dilution choice to the buyer, which is not itself a red flag, but it does mean the buyer is responsible for deriving concentration rather than reading it off the label.
Calculating Concentration From the Two Figures
Once both numbers are known, concentration is a simple division: peptide mass in milligrams divided by diluent volume in milliliters. A worked example makes the relationship concrete.
Suppose a listing states 2 mg of labeled peptide content and suggests reconstitution with 2 mL of bacteriostatic water. Concentration works out to 2 mg ÷ 2 mL = 1 mg/mL. Converting to micrograms, since 1 mg equals 1000 mcg, that same solution holds 1000 mcg/mL. On a U-100 insulin syringe, where 1 mL corresponds to 100 unit markings, each unit line drawn up therefore corresponds to 1000 mcg ÷ 100 units = 10 mcg per unit.
If the same 2 mg vial were instead reconstituted with 4 mL rather than 2 mL, the concentration would be 2 mg ÷ 4 mL = 0.5 mg/mL, or 500 mcg/mL. Each unit on a U-100 syringe would then correspond to 500 mcg ÷ 100 units = 5 mcg per unit — half the concentration per unit compared to the first example, using the identical vial and identical peptide mass. The only variable that changed was the diluent volume chosen at reconstitution, which is exactly why fill volume and peptide content need to be read as two separate inputs rather than one combined spec.
Reading a Listing Table
The table below summarizes how the two figures typically appear on a listing and what each one actually communicates.
| Label element | What it measures | Fixed at manufacture? | Buyer-controlled? |
|---|---|---|---|
| Peptide content (mg) | Mass of tesamorelin in the vial | Yes | No |
| Suggested fill/reconstitution volume (mL) | Diluent volume recommended for reconstitution | No | Yes, buyer may vary it |
| Resulting concentration (mg/mL or mcg/mL) | Peptide mass ÷ diluent volume | No | Derived, not stated directly unless calculated |
| Units per mL on a syringe | Diluent volume × 100 (U-100 scale) | No | Determined by chosen diluent volume |
What a Listing Should Make Explicit
A well-documented listing states peptide content as an unambiguous mass figure, ideally cross-referenced to a certificate of analysis that reports the same mass and confirms it independently of the label claim. If a listing also offers reconstitution guidance, that guidance should be presented as a suggestion rather than a fixed fact, since the buyer ultimately selects the diluent volume and therefore determines the concentration. Listings that blur mass and volume into a single ambiguous figure, or that describe a vial only by its liquid capacity without stating peptide mass at all, leave buyers unable to calculate concentration with any confidence.
Because fill volume is chosen after manufacturing while peptide content is fixed during it, the two numbers answer different questions. Fill volume answers “how much liquid will this vial hold once reconstituted.” Peptide content answers “how much tesamorelin was in the vial before any liquid was added.” A listing that keeps these two figures clearly separated, and a COA that independently verifies the mass figure, gives a buyer everything needed to calculate concentration correctly rather than guessing at it.
The growth hormone–IGF-1 signaling axis that tesamorelin research concerns has been characterized in multiple contexts, including a 2022 review of growth variations and IGF-1’s clinical role and a study examining GH-IGF-1 axis behavior alongside metabolic and sleep parameters. Neither source addresses vial labeling directly, but both are useful background for understanding why accurate concentration figures matter to anyone tracking dosing math in a research context.
In short, fill volume and labeled peptide content are two independent numbers on a tesamorelin listing, and only careful reconstitution math — mass divided by diluent volume — turns them into an actual concentration figure.
A note on how to read this
This article is written for research and educational reference. The materials described are sold for laboratory research and are not for human consumption. Nothing here is dosing guidance, a prescription, or a clinical recommendation.